Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation […]
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
Executive Summary: The Transatlantic Bifurcation The global life sciences industry stands at a critical juncture, navigating a bipolar regulatory order
Drugs and Devices: Comparison of European and U.S. Approval Processes Read Post »
Executive Summary: The Structural Redesign of an Industry The pharmaceutical sector, historically characterized by its defensive moats of intellectual property
Section 1: The Economic Architecture of Modern Drug Development The numbers that define pharmaceutical R&D productivity are brutal and well-documented.
Outsourcing Drug Development: The Definitive Pharma IP and Operations Playbook Read Post »
Introduction China’s pharmaceutical sector completed a structural transformation in less than a decade. The country that was processing the world’s
Part 1: What Branded Generics Are (and Why the Distinction Matters) Defining the Category A branded generic is a pharmaceutical
Branded Generics: The Profit Engine Behind Off-Patent Drug Strategy Read Post »
Section 1: Why API Strategy Is Corporate Strategy The Active Pharmaceutical Ingredient is not a line item in a chemistry
Optimizing your API strategy to deliver desired results Read Post »
Why This Comparison Matters Now The generic pharmaceutical industry generated $445 billion in U.S. system savings in 2023 alone, according
Key Takeaways (Executive Summary) Part I: The BPCIA Framework — Why ‘Abbreviated’ Is a Misnomer What the Biologics Price Competition
US Biosimilars: The Complete Barrier Map for IP Teams, Payers, and Portfolio Managers Read Post »
Sign in or create a free account to read this DrugPatentWatch article
